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Abstract Extravasation is a critical process for the physio-
logical lymphocyte traffic as well as the hematogenous spread of
malignant hemopoietic cells. Here we report that abrogation of
calcineurin activity leads to in vitro transendothelial migration
and in vivo infiltration of human lymphoma Nalm-6 cells, which
are associated with the abrogation of the VLA-4/VCAM-1
mediated pathway. Rapamycin, which can antagonize FK506 but
not CsA to inhibit calcineurin, abrogates FK-506 mediated but
not CsA mediated inhibition of in vitro transendothelial
migration. FK506 may exert its potent immunosuppressive
action partly by inhibiting VLA-4/VCAM-1 mediated transen-
dothelial migration or insinuation of lymphoid cells to tissues.
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1. Introduction
Extravasation is an essential process in lymphocyte homing
as well as systemic spreading of malignant hemopoietic cells.
It involves adhesion of hemopoietic cells to the vascular en-
dothelium [1] and transmigration through intercellular junc-
tions [2].
FK506 is known as a potent immunosuppressive agent, and
its mechanism of action is thought to be due to inhibition of
calcineurin phosphatase [3,4]. The inhibition of calcineurin
phosphatase in T cells leads to impairment of transcription
of the IL-2 gene, and thus results in immunosuppression. In
addition, FK506 has also been reported to inhibit migration
of neutrophils on coated vitronectin by a¡ecting the a⁄nity of
vitronectin receptor [5,6]. Accordingly, we postulated that the
potent immunosuppressive action of FK506 is partly due to
integrin mediated migration of immunocompetent cells.
Here we report that FK-506 inhibits VLA-4/VCAM-1
mediated events in vitro and in vivo and suggest that this is
at least partly relevant to the immunosuppressive action of
this agent.
2. Materials and methods
2.1. Cell lines
Nalm-6, a human pre-B cell line, was maintained in RPMI 1640 me-
dium (Flow Labs., Irvine, UK) containing 10% fetal calf serum,
10 mM HEPES, 2 mM L-glutamine, 1 mM sodium pyruvate, 1034
M 2-mercaptoethanol, 1% (v/v) 100Unon-essential amino acids,
100 U/ml penicillin and 100 Wg/ml streptomycin (complete RPMI).
KOP2.16, an endothelial cell line derived from mouse peripheral
lymph nodes, was maintained as described previously [7].
2.2. Mice
SCID (CD-17 scid/scid) mice aged 7 weeks were purchased from
Charles River Japan (Atsugi, Japan). They were used according to the
guidelines of the Animal Ethics Committee of the Institute.
2.3. Reagents
FK506 in crystalline form or containing a carrier solvent (HCO-60
and D-mannitol) was obtained from Fujisawa Pharmaceutical (Osaka,
Japan), rapamycin from Calbiochem (La Jolla, CA), and cyclosporin
A (CsA) from Sandoz (Basel, Switzerland). FK506 in crystalline form
(1 mg/ml), rapamycin (1 mg/ml) and CsA (10 mg/ml) were dissolved in
dimethyl sulfoxide (DMSO) and diluted to the desired concentration
immediately before use. FK506 containing carrier solvent was diluted
in phosphate bu¡ered serum (PBS) and used for in vivo treatment.
2.4. Monoclonal antibodies
Hybridomas producing SG/19 (anti-human integrin L1) [8], SG/73
(anti-human VLA-4K) [8], KH/33 (anti-human VLA-5K) [8], M/K-2
(anti-murine VCAM-1) [9], and KM201 (anti-murine CD44) [10] were
generous gifts from Dr. K. Miyake, Saga University Medical School
(Saga, Japan). GoH3 (anti-human VLA-6K) was purchased from Im-
munotech (Marseille, France). Leu-12 (anti-human CD19) conjugated
with FITC was from Becton-Dickinson (Mountain View, CA). SG/19
and SG/73 were puri¢ed from ascitic £uid produced in nu/nu mice
using caprylic acid, as described [11].
2.5. Assays for interactions between lymphoma cells and endothelial
cells
Binding was assessed as described previously [2] at 15 min after
Nalm-6 cells had been added on KOP2.16 cells. Transmigration was
assessed microscopically at 90 min after Nalm-6 cells were added onto
KOP2.16 cells, when the number of transmigrated Nalm-6 cells
reached a plateau [2]. The e¡ects of FK506, CsA, or rapamycin
were examined as follows. Nalm-6 cells or KOP2.16 cells were pre-
incubated with the agent alone or in combination at the indicated
concentrations for 2 h at 37‡C, then without washing, Nalm-6 cells
were added onto the KOP2.16 monolayer, and binding or transmigra-
tion was assessed in the presence of the test agent. We also studied the
e¡ects of mAbs. Nalm-6 cells or KOP2.16 cells were incubated with
10 Wg/ml of the indicated antibody for 30 min, then binding and
transmigration were assessed in the continued presence of the mAb.
2.6. Calcineurin phosphatase assay
Phosphatase activity was measured as 32P release from 32P-labeled
substrates as described previously [4,12].
2.7. Inoculation of Nalm-6 cells into SCID mice
Nalm-6 cells (1U107) in 0.1 ml of PBS were inoculated intrave-
nously (i.v.) into SCID mice via the tail vein. Mice were killed at
the indicated times, the gross anatomy was surveyed, and tissues
were removed for £ow cytometry and immunohistochemical analysis.
In some experiments, SCID mice were inoculated i.v. with Nalm-6
cells treated with FK506 (100 ng/ml, 37‡C, 2 h), and FK506 (3 mg/
kg of body weight) was given subcutaneously (s.c.) every day from
one day before Nalm-6 cells inoculation to the day of death. Control
mice were inoculated i.v. with Nalm-6 cells treated with the equivalent
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concentration of diluent, and the equivalent dose of carrier solvent
was given s.c. Since Nalm-6 cells express a high level of human CD19,
cell suspensions obtained from the bone marrow and spleen were
labeled with mAb Leu-12 (anti-CD19) conjugated with FITC, then
evaluated by £ow cytometry on an EPICS-Elite (Coulter, Hialeah,
FL). We also recorded the day when mice became paraplegic, an
indicator of the involvement of Nalm-6 cells in the central nervous
system.
2.8. Statistical analysis
Di¡erences in the percentage of Nalm-6 cells between FK506
treated mice and control mice were examined for statistical signi¢-
cance using a two-tailed non-parametric Wilcoxon’s test. The propor-
tion of mice that developed paraplegia was calculated by the Kaplan-
Meier method [13], and the di¡erence between proportion curves was
analyzed by the log-rank test. We considered di¡erences signi¢cant at
P6 0.05.
3. Results
3.1. FK506 inhibits transmigration by a¡ecting both Nalm-6
cells and KOP2.16 cells
When Nalm-6 lymphoma cells were added onto a con£uent
KOP2.16 endothelial cell monolayer, they initially bound to
the surface of endothelial cells and then swiftly transmigrated
underneath them [2]. To determine whether FK506 inhibits
these processes, cells were ¢rst treated with FK506 (100 ng/
ml, 2 h), and assessed for binding to and transmigration
underneath endothelial cells in the continued presence of the
agent. As shown in Fig. 1, only treatment with FK506 of both
Nalm-6 cells and KOP2.16 cells inhibited transmigration.
Treatment of either of the cell types with FK506 did not result
in inhibition. Interestingly, FK506 did not reduce the number
of Nalm-6 cells bound on the surface of KOP2.16 cells (Fig.
1), suggesting that FK506 inhibited events critical for trans-
migration after adhesion of the cells.
3.2. Correlation of calcineurin phosphatase activity with
transmigration
We next examined if the observed inhibition of transmigra-
tion by FK506 was due to inhibition of calcineurin phospha-
tase activity. After treatment of Nalm-6 cells or KOP2.16 cells
with various concentrations of FK506 or CsA for 2 h, cell
lysates were prepared and calcineurin phosphatase activity
was measured (Fig. 2B). We also studied the e¡ects of such
treatment on transmigration. Similar dose-response curves for
inhibition of calcineurin activity and transmigration was ob-
served using either FK506 or CsA (Fig. 2A,B), indicating that
the inhibition of calcineurin phosphatase activity by FK506 or
CsA closely correlated with the inhibition of transmigration.
Such inhibition by FK506 was evident at a concentration of
1 ng/ml and reached a plateau at 10 ng/ml. Similarly, inhib-
ition of calcineurin activity commenced at a comparable dose,
and 70^80% inhibition was observed at 10 ng/ml in Nalm-6
cells or KOP2.16 cells. Similar results were obtained with
CsA, although the concentrations necessary for inhibition of
calcineurin phosphatase were about 10-fold higher than those
of FK506. Combined, these results suggest that inhibition of
calcineurin phosphatase activity by FK506 is causally related
to inhibition of transendothelial migration of Nalm-6 cells.
To further investigate the relationship between calcineurin
phosphatase activity and transmigration, we next used rapa-
mycin (Fig. 2C,D), which is known to antagonize FK506 by
competitively binding to FKBP (FK506-binding protein) [3,4].
When either Nalm-6 cells or KOP2.16 cells were treated with
rapamycin (1 Wg/ml) prior to the assay or when both cells
were cultured with rapamycin during the assay, the FK506
mediated but not CsA mediated inhibition of transmigration
was no longer observed (Fig. 2C), indicating that rapamycin
speci¢cally abrogated the inhibitory e¡ect of FK506 on trans-
migration. The same dose of rapamycin also abrogated the
FK506 mediated but not CsA mediated inhibition of calci-
neurin phosphatase activity (Fig. 2D), in line with previous
reports indicating that rapamycin antagonizes FK506 but not
cyclosporin [3,4]. These results suggest that FK506 inhibits
calcineurin phosphatase activity of both Nalm-6 cells and
KOP2.16 cells, and thereby inhibits transendothelial migra-
tion.
3.3. FK506 inhibits transmigration by abrogating
VLA-4/VCAM-1 mediated transmigration
We then investigated the molecular mechanism of FK506
mediated inhibition of transmigration. Since integrins have
been implicated in transendothelial migration of lymphoid
cells [14,15], we ¢rst examined the involvement of VLA-4
and VLA-5 expressed in Nalm-6 [8] in transmigration. As
shown in Fig. 3A, transmigration underneath KOP2.16 cells
expressing VCAM-1 [7] was signi¢cantly inhibited by mAbs
against VLA-4K, VLA-5K, anti-VLA L chain (anti-L1) and
also by mAb against VCAM-1. However, none of these
mAbs a¡ected adhesion of Nalm-6 cells to KOP2.16 cells
(Fig. 3B), indicating that VLA-4, VLA-5 and VCAM-1 were
involved in the transmigration process but not in adhesion. In
addition, the observations that anti-VCAM-1 inhibited trans-
migration to the same extent as did anti-VLA-4K and that the
combination of the two mAbs resulted in no further inhibition
(Fig. 3A) suggested that VLA-4 on Nalm-6 interacted with
VCAM-1 on KOP2.16, leading to transmigration in coopera-
tion with VLA-5. In line with this conclusion, anti-VLA-5
acted additively with anti-VLA-4 or anti-VCAM-1 in inhibit-
ing transmigration (Fig. 3A).
We then investigated whether the FK506 induced inhibition
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Fig. 1. FK506 inhibits transendothelial migration but not adhesion
of Nalm-6 cells. Nalm-6 and KOP2.16 were pretreated with FK506,
and transmigration or adhesion of cells was evaluated in the pres-
ence of FK506. Cells pretreated with an equivalent concentration of
diluent were used as control. Data are results of three independent
experiments and are expressed as mean þ S.D. of percent of control
calculated as follows: % control = (migration or binding of FK506
pretreated cells in the presence of FK506/migration or binding of
control cells in the presence of the diluent alone)U100.
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of transmigration of Nalm-6 could be explained by down-
regulation of these integrin dependent pathways. Following
treatment of cells with FK506, neither anti-VLA-4K nor
anti-VCAM-1 inhibited transmigration of Nalm-6, whereas
anti-VLA-5K induced inhibition did not change (Fig. 3C).
Flow cytometric analysis showed that treatment with FK506
did not change the expression level of VLA-4 or VCAM-1 on
respective cells (data not shown). These ¢ndings suggest that
treatment with FK506 abrogated mainly the VLA-4/VCAM-1
mediated transmigration process without compromising the
expression level of VLA-4 or VCAM-1.
3.4. FK506 inhibits in¢ltration of Nalm-6 cells to the bone
marrow and spleen, but not to the central nervous system
(CNS) in SCID mice
In the next series of experiments we examined whether
FK506 can a¡ect VLA-4/VCAM-1 dependent lymphoid cell
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Fig. 3. Transendothelial migration but not adhesion of Nalm-6 is
mediated by VLA-4/VCAM-1 interaction, and FK506 selectively
downregulates VLA-4/VCAM-1 dependent transmigration. Antibody
treatment was performed at a concentration of 10 Wg/ml at 37‡C for
30 min, and then transmigration (A) or binding (B) was assessed in
the continued presence of the antibodies. The e¡ect of FK506 on
transmigration was then examined in the presence of various mAbs
in the assay system (C) as described in Section 2.
Fig. 2. Inhibition of transmigration of Nalm-6 closely correlated
with inhibition of calcineurin phosphatase activity in Nalm-6 as well
as in endothelial cells. A: Dose dependent inhibition of transmigra-
tion with calcineurin inhibitors. B: Dose dependent inhibition of
phosphatase activity of calcineurin with FK506 or CsA in Nalm-6
(upper panel) or KOP2.16 endothelial cells (lower panel). Both
Nalm-6 and KOP2.16 cells were treated with the indicated concen-
trations of FK506 (closed circles) or CsA (open circles). This was
followed by determination of calcineurin phosphatase activities in
Nalm-6 (upper panel) and KOP2.16 (lower panel). The extent of in-
hibition was calculated as described in the legend of Fig. 1. C: Ab-
rogation of FK506 mediated inhibition of transmigration with rapa-
mycin. Nalm-6 or KOP2.16 were pretreated with or without 1 Wg/
ml of rapamycin (indicated as + or 3 on the left side of the graph)
before they were treated with FK506 (100 ng/ml) or CsA (1 Wg/ml),
and transmigration assay was performed in the presence or absence
of rapamycin. When FK506 or CsA was used, the assay was per-
formed in the presence of the corresponding reagent. D: Abrogation
of FK506 mediated inhibition of calcineurin activity with rapamy-
cin. Cells were pretreated with calcineurin inhibitors alone or in
combination with 1 Wg/ml of rapamycin, and then phosphatase ac-
tivity of calcineurin was evaluated.
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migration in vivo. SCID mice were i.v. inoculated with Nalm-
6 cells (1U107) pretreated with or without FK506 (100 ng/ml,
2 h at 37‡C) in vitro. The same animals were then treated with
s.c. injections of FK506 (3 mg/kg) or vehicle alone every day.
Mice were killed at 33^37 days after inoculation of Nalm-6
cells, and hematogenous spread of Nalm-6 cells to the bone
marrow, spleen and CNS was examined (Fig. 4A,B). The
selection of these tissues was based on the constitutive expres-
sion of a VLA-4 ligand, VCAM-1, in the bone marrow and
spleen [16^19], while CNS does not express these molecules
under physiological conditions [20,21]. In control mice, Nalm-
6 cells invariably in¢ltrated into the bone marrow as well as
CNS consistent with previous studies [22] and also in¢ltrated
the spleen to various degrees. In¢ltration into the bone mar-
row was particularly extensive, and more than 80% of the cells
obtained from the marrow were identi¢ed as CD19 bright
positive Nalm-6 cells at the time of death in all animals exam-
ined (Fig. 4A). In¢ltration into CNS was also prominent,
which caused progressive paraplegia in tumor inoculated
mice (Fig. 4B). In contrast, treatment of mice with FK506
markedly reduced the number of Nalm-6 cells that in¢ltrated
into the bone marrow and spleen relative to control mice, and
in particular, colonization into the spleen was markedly and
uniformly reduced (Fig. 4A). However, the proportion of
FK506 treated mice that developed paraplegia was not di¡er-
ent from control mice (Fig. 4B), indicating that the CNS in-
volvement was little a¡ected by FK506. Thus, FK506 sub-
stantially inhibited hematogenous spread of VLA-4 positive
Nalm-6 cells to VCAM-1 expressing bone marrow and spleen
but not that into the CNS which expresses little or no VCAM-
1 under physiological conditions.
4. Discussion
The major ¢nding of the present study was that FK506
inhibited transendothelial migration of Nalm-6 lymphoma
cells and that this inhibition was not due to inhibition of
cell adhesion but largely due to abrogation of the VLA-4/
VCAM-1 dependent transmigration process. Inhibition of
transmigration closely correlated with inhibition of calcineu-
rin phosphatase activity.
That inhibition of calcineurin phosphatase activity was at
least partly responsible for inhibition of transmigration was
based on the following results. First, not only FK506 but also
CsA, another inhibitor of calcineurin phosphatase, signi¢-
cantly inhibited transendothelial migration of Nalm-6 cells.
Second, dose-response studies with FK506 and CsA showed
that inhibition of transmigration closely correlated with inhib-
ition of calcineurin phosphatase activity of Nalm-6 and
KOP2.16 cells. Third, rapamycin, which antagonizes FK506
but not CsA by competitively binding FK506 binding protein
[3,4], inhibited FK506 mediated but not CsA mediated inhib-
ition of transmigration. However, the inhibitory e¡ect of
FK506 on transendothelial migration may not be explained
solely by inhibition of calcineurin phosphatase. As shown in
Fig. 1, to signi¢cantly inhibit transmigration both Nalm-6 and
KOP2.16 cells had to be pretreated with FK506 which also
had to be present throughout the assay. Removal of FK506
from the assay abrogated the inhibition of transmigration,
although preliminary experiments indicated that calcineurin
phosphatase activity of Nalm-6 cells or KOP2.16 cells re-
mained inhibited at a comparable level after removal of
FK506 for at least 90 min (data not shown). This period
should have been su⁄cient for Nalm-6 cells to undergo trans-
endothelial migration. Therefore, it appears that inhibition of
calcineurin phosphatase alone may not be su⁄cient for inhib-
ition of transmigration. A similar observation has been re-
ported in FK506 mediated inhibition of neutrophil motility
in that the motility on coated vitronectin was inhibited only
in the continued presence of the agent and not when FK506
was removed before the addition of neutrophils on vitronectin
[5,6].
Antibody blocking experiments indicated that transendo-
thelial migration of Nalm-6 cells was largely (V80%) depend-
ent on L1 integrins with VLA-4 and VLA-5 contributing
equally and that VLA-4 on Nalm-6 was involved by recogniz-
ing VCAM-1 on endothelial cells. Since mAb against VLA-4,
VLA-5, VCAM-1 and the integrin L1 chain inhibited trans-
migration without a¡ecting cell adhesion, it was reasoned that
the mAb mediated e¡ects were speci¢c and that the recog-
nized molecules mediate transmigration preferentially. The
molecule(s) principally involved in cell adhesion is currently
unknown. Since FK506 treatment completely abrogated mAb
induced inhibition of transmigration by anti-VLA-4 and/or
anti-VCAM-1 without a¡ecting anti-VLA-5 induced inhibi-
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Fig. 4. FK506 inhibits in¢ltration of Nalm-6 cells into the spleen
and bone marrow but not CNS in SCID mice. A: In¢ltration of
Nalm-6 cells into the spleen (left panel) and bone marrow (right
panel) as assessed by £ow cytometry. Results are presented as per-
centage of CD19 Nalm-6 cells among total nucleated cells of each
organ. B: Comparison of the percentage of mice who developed
paraplegia, among mice injected with Nalm-6 and later treated or
untreated with FK506.
S. Tsuzuki et al./FEBS Letters 430 (1998) 414^418 417
tion, it is likely that the inhibition was through selective
downregulation of the VLA-4/VCAM-1 dependent pathway,
although its precise mechanism is currently unclear. It is of
note in this respect that a rise in intracellular Ca2 is required
to activate Ca2/calmodulin dependent calcineurin phospha-
tase [3] and that lymphocyte adhesion to endothelial cells can
induce a rise in intracellular Ca2 in both cell types [23].
Furthermore, VLA-4/VCAM-1 interaction has been actually
shown to trigger Ca2 mobilization in both lymphoid and
endothelial cells [24]. Hence, one possibility is that interac-
tions between VLA-4 and VCAM-1 elicited a rise in intra-
cellular Ca2 in both Nalm-6 cells and KOP2.16 cells, thus
leading to activation of calcineurin phosphatase, which re-
sulted in initiation of transmigration by an as yet unde¢ned
mechanism. In addition, it has been reported previously that
the a⁄nity/avidity of lymphocyte VLA-4 increases transiently
during the transendothelial migration process, which appar-
ently initiates transmigration [25]. This might also apply to
Nalm-6 and that the a⁄nity/avidity of VLA-4 on Nalm-6 cells
could be controlled by a calcineurin dependent process where
calcineurin of both Nalm-6 and endothelial cells are required,
which may in part account for the need to treat both cell types
with FK506 simultaneously to induce a signi¢cant inhibition
of transmigration. Another possibility is that inhibition of
transmigration was caused by a failure of reduction of integ-
rin a⁄nity, which would result in a decrease of de-adhesion,
and hence reduction of cell motility [5,6].
Results of in vivo studies also supported the notion that
FK506 can preferentially a¡ect VLA-4/VCAM-1 dependent
pathway. Thus, although Nalm-6 cells in¢ltrated into both
VCAM-1 positive tissues (bone marrow and spleen) and
VCAM-1 negative tissues such as CNS, FK506 selectively
inhibited in¢ltration into VCAM-1 positive tissues. This in-
hibition was apparently not caused by inhibition of prolifer-
ation of Nalm-6 cells, since preliminary experiments indicated
that up to 1000 ng/ml of FK506 did not inhibit proliferation
of Nalm-6 during a 5 day culture period, and that concentra-
tions in peripheral blood of FK506 treated mice were far low-
er than that (136.6 þ 17.0 ng/ml) at death (n = 3) (data not
shown).
In summary, the results of our experiments indicate that
FK506 inhibited calcineurin of both Nalm-6 cells and endo-
thelial cells, which caused downregulation of VLA-4/VCAM-1
mediated transendothelial migration process. Although a mo-
lecular link between calcineurin and VLA-4/VCAM-1 depend-
ent transmigration pathway remains unknown, we infer from
the results of the present study that FK506 might exert its
immunosuppressive e¡ect partly by inhibiting the exit of lym-
phocytes from blood to the site of immunoreaction, where
expression of VCAM-1 is constitutively expressed or possibly
induced by cytokines.
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